Talmadge J E, Lenz B F, Pennington R, Long C, Phillips H, Schneider M, Tribble H
Cancer Res. 1986 Sep;46(9):4505-10.
In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.
在本报告中,我们描述了贝司他汀的免疫调节特性和治疗效果。在体外和体内均观察到巨噬细胞活化,但未观察到自然杀伤细胞增加。在同种异体混合淋巴细胞反应试验中观察到T细胞活性的免疫刺激,但同种异体混合淋巴细胞-肿瘤细胞培养后未产生细胞毒性效应细胞。当贝司他汀与由照射过的肿瘤细胞组成的次优疫苗混合时,它也具有T细胞佐剂活性。当以高剂量对每只动物给药4周时,我们观察到贝司他汀对预先存在的实验性和自发性转移具有显著的治疗活性。